Dr. Reddy’s Laboratory was granted the approval by the Drug Controller General of India (DCGI) to conduct the phase 2 and 3 of trials. The first phase of Russia’s Covid-19 vaccine Sputnik V is likely to reach Kanpur’s Ganesh Shankar Vidyarthi College by next week.
According to sources, more than 180 volunteers registered to be part of the clinical trial of the Sputnik V vaccine’s phase 2 & 3 trials that is to be conducted by Dr Reddy’s Laboratories. The principal of the Kanpur Medical College, KB Kamal, in an interview to Press Trust Of India said that the clinical trials of the Covid-19 vaccine will be conducted starting from the next week.
“The research head Dr. Saurabh Agarwal will determine the dose of the vaccine. One dose will be administered and the condition of the volunteers will be monitored to determine whether they need further doses or not.” – Principal KB Kamal said.
A spokesperson of Dr. Reddy’s laboratory said “Phase-II clinical trials will start in a few weeks and expected to complete by December-end.’’
A spokesperson of Dr. Reddy’s laboratory said “Phase-II clinical trials will start in a few weeks and expected to complete by December-end.’’
The Russian Direct Investment Fund, a sovereign wealth fund body of Russian tied up with the laboratory giant Dr. Reddy’s for the later phase of trials of their Sputnik V COVID-19 vaccine.
According to sources, RDIF (Russian Direct Investment Fund) will supply 100 million doses to India in this phase of trial.
The Russian Direct Investment Fund, a sovereign wealth fund body of Russian tied up with the laboratory giant Dr. Reddy’s for the later phase of trials of their Sputnik V COVID-19 vaccine.
According to sources, RDIF (Russian Direct Investment Fund) will supply 100 million doses to India in this phase of trial.
